Goldman Sachs analyst Chris Shibutani reiterated a Buy rating and $51.00 price target on Royalty Pharma (NASDAQ: RPRX).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE